In vitro flow cytometry method to quantitatively assess inhibitors of P- glycoprotein

Drug Metabolism and Disposition

Volumn 28, Issue 5, 2000, Pages 522-528

  Wang, Er Jia ^a   Casciano, Christopher N ^a   Clement, Robert P ^a   Johnson, William W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CYCLOSPORIN A; DAUNORUBICIN; GLYCOPROTEIN P; NICARDIPINE; PROTEIN INHIBITOR; QUINIDINE; TAMOXIFEN; TERFENADINE; TETRAPHENYLPHOSPHONIUM; VERAPAMIL; VINBLASTINE;

ANALYTIC METHOD; ARTICLE; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG POTENCY; DRUG TRANSPORT; FLOW CYTOMETRY; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CALCIUM CHANNEL BLOCKERS; CELL SURVIVAL; CELLS, CULTURED; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MICROSCOPY, FLUORESCENCE; P-GLYCOPROTEINS; TUMOR CELLS, CULTURED; VANADATES; VERAPAMIL;

EID: 0034094322     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Al-Shawi MK and Senior AE (1993) Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein. J Biol Chem 268:4197-4206.
2. Baggetto LG, Dong M, Bernaud J, Espinossa L, Rigal D, Bonvallet R and Marthinet E (1998) In vitro and In vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin. Biochem Pharmacol 56:1219-1228.
3. Broxterman HJ, Schuurhuis GJ, Lankelma J, Oberink JW, Eekman CA, Claessen AME, Hoekman K, Pool M and Pinedo HM (1997) Highly sensitive and specific detection of P-glycoprotein function for haematological and solid cells using a novel nucleic acid stain. Br J Cancer 76:1029-1034.
4. Chin KV, Pastan I and Gottesman MM (1993) Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60:157-180.
5. Chin-Yee I, Crowther MA, Keeney M, Wright L and Daly S (1994) Validation of a single flow cytometric assay for determining P-glycoprotein activity in multidrug resistant cell lines. Clin Lab Haematol 16:261-272.
6. Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL and Farkas DH (1995) Immunohistochemical analysis of P-glycoprotein expression in breast cancer: Clinical correlations. Ann Clin Lab Sci 25:52-59.
7. Gheuens EE, van der Heyden SA, Elst HE, Van Oosterom AT and De Bruijn EA (1997) Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells. Cancer Detect Prev 21:78-82.
8. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
9. Gros P, Talbot F, Tang-Wai D, Bibi E and Kaback HR (1992) Lipophilic cations: A group of model substrates for the multidrug-resistance transporter. Biochemistry 31:1992-1998.
10. Frey T, Yue S and Haugland RP (1995) Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance. Cytometry 20:218-227.
11. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ and Wrighton SA (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161-166.
12. Hyafil F, Vergely C, Du Vignaud P and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
13. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE and Higgins CF (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature (Lond) 346:362-365.
14. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P and Hiestand PC (1992) SDZ PSC 833, a non-immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 50:593-597.
15. Krishan A and Ganapathi R (1980) Laser flow cytometric studies on intracellular fluorescence of anthracyclines. Cancer Res 40:3895-3900.
16. Krishan A, Sridhar KS, Davila E, Vogel C and Stemheim W (1987) Patterns of anthracycline retention modulation in human tumor cells. Cytometry 8:306-314.
17. Lampidis T, Munck J, Krishan A and Tapiero H (1985) Reversal of resistance to rhodamine 123 in adriamycin-resistant Friend leukemia cells. Cancer Res 45:2626-2631.
18. Ling V (1995) P-glycoprotein: Its role in drug resistance. Am J Med 99: 31S-34S.
19. Loo TW and Clarke DM (1995) Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. J Biol Chem 270:22957-22961.
20. Maynadie M, Lizard G, Solary E, Roignot P and Carli P-M (1994) Multidrug resistance phenotype evaluation by immunofluorescence and functional tests: Comparison of two monoclonal antibodies and three fluorescent dyes in three cells lines. Anticancer Res 14:2605-2610.
21. Merlin JL, Marchai S, Ramacci C, Dieterlen A, Schultz G, Lucas C, Poullain MG and Berlion M (1995) Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells. Cytometry 20:315-323.
22. Nooter K, van den Engh G and Sonneveld P (1983) Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells. Cancer Res 43:5126-5130.
23. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC and Beck WT (1989) Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 86:5128-5132.
24. Redmond SM, Joncourt F, Buser K, Ziemiecki A, Altermatt HJ, Fey M, Margison G and Cerny T (1991) Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and 06-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51:2092-2097.
25. Relling MV (1996) Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18:350-356.
26. Ross DD, Doyle LA, Yang W, Tong Y and Comblatt B (1995) Susceptibility of idarubicin. daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol 50:1673-1683.
27. Sato W, Fukazawa N, Suzuki T, Yusa K and Tsuruo T (1991) Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 51:2420-2424.
28. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ and Borst P (1995) Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A: 1295-1298.
29. Shapiro AB and Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130-137.
30. Slate DL, Bruno NA, Casey SM, Zutshi N, Garvin U, Wu H and Pfister JR (1995) RS-33295-(198): A novel, potent modulator of P-glycoprotein-mediated multidrug resistance. Anticancer Res 15:811-814.
31. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B and Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 340:255-259.
32. Toffoli G, Simone F, Corona G, Raschack M, Cappelletto B, Gigante M and Boiocchi M (1995) Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem Pharmacol 50:1245-1255.
33. Urbatsch IL, Sankaran B, Bhagat S and Senior AE (1995) Both P-glycoprotein nucleotide-binding sites are catalytically active. J Biol Chem 270:26956-26961.
34. Wang G, Pincheira R and Zhang JT (1998) Dissection of drug-binding-induced conformational changes in P-glycoprotein. Eur J Biochem 255:383-390.
35. Watanabe T, Tsuge H, Oh-Hara T, Naito M and Tsuruo T (1995) Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34:235-241.
36. Wishart GC, Plumb JA, Morrison JG, Hamilton TG and Kaye SB (1992) Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 28:28-31.